A Cancer Research UK First Time in Human Phase I Trial of IMA950 (Novel Multi-Peptide Therapeutic Vaccine) in Patients with Newly Diagnosed Glioblastoma

PURPOSE: To perform a two-cohort, phase 1 safety and immunogenicity study of IMA950 in addition to standard chemo-radiotherapy (CRT) and adjuvant temozolomide in patients with newly diagnosed glioblastoma (GBM). IMA950 is a novel GBM specific therapeutic vaccine containing 11 tumor-associated peptid...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Clin Cancer Res
Auteurs principaux: Rampling, Roy, Peoples, Sharon, Mulholland, Paul J., James, Allan, Al-Salihi, Omar, Twelves, Christopher J., McBain, Catherine, Jefferies, Sarah, Jackson, Alan, Stewart, Willie, Lindner, Juha, Kutscher, Sarah, Hilf, Norbert, McGuigan, Lesley, Peters, Jane, Hill, Karen, Schoor, Oliver, Singh-Jasuja, Harpreet, Halford, Sarah E., Ritchie, James W.A.
Format: Artigo
Langue:Inglês
Publié: 2016
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5026298/
https://ncbi.nlm.nih.gov/pubmed/27225692
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-0506
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires